Cupid Limited (NSE: CUPID, BSE: 530843) announced on 28 August 2026 that its Board of Directors has accorded in-principle approval for the establishment of a manufacturing venture in South Africa with a South African partner. According to reports from Business Standard, the proposed venture aims to establish a suitable entity and manufacturing facility in South Africa for the manufacture, processing, testing, packaging, marketing and supply of male condoms and related products. The company disclosed this development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, referencing SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026.
Under the proposed structure, Cupid is expected to hold up to 49% of the equity share capital, while the South African partner and/or its qualifying local shareholders would hold at least 51% and retain control, as reported by Business Standard. This ownership arrangement aligns with applicable South African ownership, localisation, transformation, procurement and tender requirements. The Indian manufacturer will contribute technical expertise, know-how, technology-transfer support, quality-control systems, and training to the venture. Crucially, the local partner will finance 100% of the capital expenditure, working capital, and operating costs, eliminating upfront balance sheet risk for Cupid. The approval is conditional on finalising definitive agreements, with further updates to be filed under SEBI Regulation 30.
The manufacturing venture represents Cupid's strategic expansion into the South African market, positioning the company to establish a local manufacturing presence for male condoms and related products. According to Business Standard, the proposed facility would handle the complete value chain from manufacturing to supply chain operations, supporting the company's regional market development strategy. Cupid currently participates in the ongoing RT75-2025 five-year tender for male and female condoms through its local business arrangements. The proposed facility could provide Cupid with a local manufacturing and distribution platform in South Africa, supporting participation in domestic institutional and government procurement programmes. Over time, subject to regulatory approvals, the venture may also create opportunities to serve additional international markets, including those in the Western Hemisphere.
In August 2026, Cupid reported excellent Q1 FY27 results with total income jumping ≈142% YoY to ₹156.98 crore (derived: ₹156.98 crore vs ₹64.75 crore) and consolidated net profit soaring 194.1% YoY to ₹44.1 crore. The company has upgraded its FY27 revenue guidance to ₹725 crore – ₹750 crore, demonstrating strong operational performance. Additionally, promoter and CMD Aditya Kumar Halwasiya acquired 13.95 lakh shares in the open market on August 17, 2026, showcasing high internal conviction in the company's growth trajectory. The company's international B2B healthcare business continued to see robust demand across institutional procurement programmes, government tenders and private export markets, providing strong order visibility and a healthy revenue pipeline.
The joint venture requires execution of final definitive agreements between Cupid and its South African partner, followed by commissioning milestones. Cupid's domestic Palava manufacturing facility commissioning is scheduled for Q2 FY27, while quarterly updates on the five-year, ₹115 crore annual South African procurement program will continue. The partner-funded joint venture model aligns with global healthcare procurement programs' increasing emphasis on localized production and regional value addition, positioning Cupid favorably to comply with domestic sourcing mandates in the region.
